Advancing Production With the MINItrace Magni

The newly certified MINItrace Magni is an automated, self-shielded cyclotron developed for in-house radioisotope manufacturing. Intended to produce Carbon-11, Fluorine-18, Nitrogen-13, and Oxygen-15, the compact unit automates beam tuning, target irradiation, and target preparation via a three-click operational interface.

When operated alongside the company’s TRACERcenter Solutions, the system fits into wider PET radiopharmacy setups to accommodate specific departmental and tracer manufacturing demands. Integrating this advanced equipment streamlines complex daily operations within modern PET radiopharmacy setups, ensuring consistent and efficient radioisotope manufacturing for medical facilities.

Broadening the PETtrace Solid Target Platform

At the same time, GE HealthCare has added Copper-64 capabilities to its PETtrace Solid Target Platform. The solid-target hardware was initially introduced for Gallium-68 in 2022 and subsequently adapted for Zirconium-89 in early 2026.

The latest addition broadens the isotope range that can be processed using PETtrace equipment, allowing facilities to expand their tracer output. The ongoing expansion of the PETtrace Solid Target Platform empowers clinical researchers and healthcare providers to scale their production capabilities without compromising precision.

Clinical Applications and Diagnostic Imaging

Copper-64 provides diagnostic imaging and is being investigated alongside Copper-67 agents as a potential diagnostic and therapeutic theranostic pairing. Clinical researchers are currently studying compounds labelled with Copper-64 in prostate cancer as well as human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Consistent diagnostic imaging is essential to support this critical work, and the company actively couples cyclotrons and targetry with synthesis chemistry and imaging tools.

Strategic Growth in Molecular Imaging

GE HealthCare molecular imaging vice-president Erez Levy said: “The molecular imaging landscape is being reshaped by the expansion of theranostics, the introduction of new PET tracers, and demand across oncology, neurology and cardiology.”

“As tracer portfolios broaden, healthcare providers need reliable access to radioisotopes and the flexibility to respond to changing clinical needs,” Levy explained. “That calls for a longer-term view of radiopharmaceutical production—one that supports established services while allowing institutions to prepare for new clinical and research applications.”

This forward-looking approach to molecular imaging aligns with recent strategic expansion moves by the healthcare technology provider.

Earlier this year, GE HealthCare partnered with Mass General Brigham to explore generative AI applications in radiotherapy.

Organized by Messe Düsseldorf (Shanghai) Co., Ltd., Medical Fair China (MFC) 2026 successfully concluded on August 22, 2026, at Suzhou International Expo Center. Under the theme “From Innovation to Application: Driving Medical Transformation and Global Expansion,” the exhibition brought together medical device companies, healthcare institutions, research organizations, industry associations and professionals from China and abroad.

This year, MFC brought together 320 medical device companies and innovative organizations, attracting 17,486 professional visitors, healthcare representatives, experts, academics and industry professionals over three days. The exhibition also saw a significant increase in international participation, with the number of overseas professional visitors and buyers doubling from the previous year and accounting for 6% of total attendance. Visitors from 48 countries and regions attended the show, including buyer groups from Germany, the UK, Australia, Canada, Kazakhstan, South Korea, India, Dubai, Malaysia, Indonesia and Romania. They met with Chinese medical device companies to discuss product procurement, market access, distribution partnerships and international business opportunities, providing more opportunities for Chinese companies to explore overseas markets.

As the only satellite event of MEDICA—the world’s largest medical trade fair—in China and a member of MEDICARE ASIA, MFC continues to leverage Messe Düsseldorf’s global healthcare industry network to facilitate international exchange and industry cooperation.

Ms. Evian Gu, General Manager of Messe Düsseldorf (Shanghai) Co., Ltd., said: “We are delighted to see that this year’s MFC has reached a new high in internationalization, which fully demonstrates the strong appeal of China’s medical device innovation to the global market. Looking ahead, MFC will continue to leverage its advantages as an international platform, further deepen international buyer outreach and market matchmaking services, help more Chinese companies efficiently connect with global opportunities, and accelerate the implementation and commercialization of more innovative outcomes, injecting new momentum into the mutual benefit and win-win development of the global medical industry.”

Driving Innovation from Concept to Application Across Specialized Zones

In 2026, MFC further enhanced its specialized zones to address the evolving needs of healthcare innovation and application. Covering key areas including in vitro diagnostics (IVD), home healthcare, medical manufacturing, minimally invasive and interventional technologies, and medical consumables, the exhibition brought together leading companies to showcase innovative technologies, products and solutions, highlighting the industry’s continued transition from innovation to real world application.

IVD Zone: From Precision Diagnostics to Multi-Scenario Applications

In vitro diagnostics (IVD) play a critical role in early disease screening, precision diagnosis and treatment decision-making. This year, MFC placed greater emphasis on its dedicated IVD Zone, bringing together more than 60 companies across molecular diagnostics, point-of-care testing (POCT), immunodiagnostics, biochemical testing, AI-assisted analysis and home testing. The zone showcased innovations spanning the spectrum from laboratory and clinical diagnostics to home health applications.

In precision and molecular diagnostics, Anbio Biotech, Nanjing Healed and HymonBio presented technologies and solutions for genetic testing, nucleic acid testing and precision diagnostics. In rapid and point-of-care testing, Drophil Biotech, Sun Biotech, QL Biotech and Anhui DeepBlue Medical Technology showcased solutions designed to improve testing efficiency and enable faster decision-making across diverse healthcare settings. Meanwhile, Getein Biotech, Kanghua Biotechnology, Human Metabolomics, Synsorbio, Hebei Xinle, Hangzhou Testsea, B&E, Sejoy, Bioland and Biobase featured intelligent testing technologies, laboratory equipment and related solutions.

Representative innovations on display further highlighted the expansion of IVD technologies toward greater precision, intelligence and home-based applications. These included Nanjing Healed’s four-in-one circular RNA test kit for depression and Sejoy’s new-generation 4G cloud-based smart blood glucose meter, demonstrating how IVD innovation is evolving across different application scenarios, from precision diagnostics to digital health management.

Home Healthcare Zone: Bringing Healthcare from Hospitals into the Home

As population ageing, chronic disease management and demand for home-based healthcare continue to grow, MFC placed greater emphasis on the home healthcare sector, covering health monitoring, home care, rehabilitation and health management. Companies including Zepu, Hanvon Health, Pango, Lumi, Jinfu, Aofeite, Lifemed, Berrcom, Exanovo and ADSS, as well as Pioneer, showcased a diverse range of products and solutions designed to support healthcare beyond traditional clinical settings.

Exhibitors showcased innovative solutions for health monitoring, home care and rehabilitation, supporting more convenient everyday health management. The zone highlighted the continued expansion of healthcare services beyond hospitals into homes and communities, reflecting the industry’s growing focus on real-world needs and applications.

Medical Manufacturing Zone: Advanced Manufacturing Enabling Medical Device Innovation

Innovation in medical devices depends not only on end products, but also on advances in precision manufacturing, critical components and materials. The MFC Medical Manufacturing Zone covered precision machining, smart manufacturing, advanced materials, fluid technology and critical components, bringing together companies including Chung Pak, Huayi Precision, AccuPath, Eco Polymer, Kamoer, Nisus, MISHPREC, Consensic and Zhejiang Hongchang Machinery.

Exhibitors showcased technologies in precision machining, medical materials, fluid control, automation and critical components, supporting greater precision, efficiency and stability in medical device manufacturing. The zone also highlighted the growing integration of advanced manufacturing with medical device R&D and production.

Meanwhile, the Minimally Invasive & Interventional Zone showcased innovative technologies and advanced medical devices for minimally invasive diagnosis and treatment. The Medical Consumables Zone featured a wide range of products for surgery, nursing, treatment and everyday healthcare, highlighting their role in enhancing clinical efficiency, supporting patient safety and improving healthcare delivery.

Many exhibitors noted that MFC offered more than a platform for showcasing innovation, providing valuable opportunities to connect directly with healthcare institutions, research organizations, distributors and international buyers.

Xu Zheng, Head of the Kunshan Service Center at LINGKE ULTRASONICS, said: “MFC offers a professional atmosphere and brings together well-matched exhibitors and visitors. It gave us a valuable opportunity to meet industry customers and potential partners, while gaining a better understanding of market needs and trends. We look forward to continuing our involvement in MFC and collaborating with more industry partners in the future.”

Cheng Wenhui, Head of International Marketing at Shandong Ande Health, said: “MFC is an important link between Chinese innovation and international markets. The show gave us a good opportunity to present our products and meet overseas customers. We hope to reach more international markets through MFC.”

From exhibitors to professional visitors, MFC provided a valuable opportunity for both sides of the industry to meet face to face and gain a better understanding of the market. Mehrad, Purchasing Manager at Lian Trade, Iran, said: “This was my first time at Medical Fair China in Suzhou, and I was impressed by the wide range of medical device products. The show gave me a good opportunity to meet Chinese companies and explore potential cooperation.”

High-Level Concurrent Events Explore New Opportunities for Medical Innovation and Industry Development

Alongside the exhibition, MFC hosted a series of professional forums, seminars and industry events, bringing together 120 experts and speakers from healthcare institutions, research organizations, industry associations, medical technology companies and international markets, and attracting 1000 industry attendees. Discussions covered key topics including AI, wearable technologies, home healthcare, medical procurement, high-quality hospital development and international market expansion, strengthening connections between emerging technologies, clinical needs and real-world applications.

As a key event dedicated to the future of healthcare innovation, the 2026 FTR4H – Future for Healthcare Forum, organized by Wearable Technology AG, brought together experts and industry representatives from China and abroad to explore AI and data analytics, wearable technologies and home healthcare. Dr. Iyappan Gunasekaran from the for Cardiovascular Health Engineering (COCHE), Hong Kong, shared insights into the application of AI and data technologies in healthcare, while Eric Zhang from Haleon discussed developments in health technology. Speakers from Yisheng Innovation Technology, AP Infosense, Solventum and Bosch, among others, shared perspectives on digital health, wearables, healthcare data and innovative applications. Through keynote presentations and panel discussions, the forum explored how AI, sensors and digital technologies can drive innovation in healthcare delivery and accelerate the transition from technology development to real-world applications.

Addressing international healthcare markets and the global expansion of Chinese medical device companies, the Kazakhstan Medical Procurement Forum brought together healthcare and procurement representatives to discuss market demand, medical device procurement and international cooperation. Ali Nurgozhayev, Director of the Institute of Health Economics and Financing, and Assem Imandossova, Executive Director of the Kazakhstan Healthcare Managers Association, shared insights into the Kazakh healthcare market and procurement landscape. The forum also facilitated direct dialogue between international buyers and Chinese companies on market access, product demand and potential partnerships, supporting business expansion in Central Asia.

As innovation increasingly connects technology development with clinical practice, the 2nd Seminar on Empowering High-Quality Hospital Development through Innovative Technologies, organized by the China Association for the Promotion of Rehabilitation Technology Transformation and Development, focused on hospital discipline development under the 15th Five-Year Plan, medical technology innovation and research translation. Discussions explored how innovative technologies can better address clinical needs and accelerate the adoption of new solutions, while strengthening collaboration among hospitals, research institutions and medical device companies.

In addition, the 2026 Emergency Medical Alliance Series – Empowering Integrated Medical and Elderly Care through Fine Medical-Engineering Management, hosted by the Chinese Hospital Association and supported by Messe Düsseldorf (Shanghai), was held concurrently in Hall A. Hospital and healthcare professionals discussed medical-engineering collaboration, refined management and integrated medical and elderly care. Their participation further reflected MFC’s strong reach among targeted professional audiences, particularly healthcare institutions, providing more direct connections between medical device companies and end users.

From future healthcare technologies and international medical procurement to home testing, consumer healthcare and hospital innovation, MFC’s concurrent events brought together professionals from across the healthcare industry. Attendees also praised the practical value of the forums. Mrs. Yuan, Deputy Director of Operations at Jianxin Medical, said: “The forum covered timely topics and gave us useful insights into healthcare supply chains and new ideas for future cooperation.”

The exhibition and forums together connected innovation, clinical needs, industry applications and global markets, supporting the adoption of new technologies and closer industry collaboration.

With MFC 2026 now concluded, the exhibition not only showcased the latest innovations in medical technology, but also strengthened connections between technological innovation, clinical applications, industry collaboration and international cooperation, providing a professional and efficient platform for Chinese and international medical device companies to explore partnerships and share new opportunities.

The next edition of Medical Fair China (MFC 2027) will take place on August 19-21, 2027, at Suzhou International Expo Center. MFC looks forward to once again bringing together partners from across the global healthcare industry, showcasing more cutting-edge technologies and innovative solutions, and exploring new pathways from innovation to application.

Meanwhile, MEDICA 2026, the world’s leading medical trade fair, will take place from November 16 to19, 2026, in Düsseldorf, Germany. The global medical community will gather there to exchange insights on emerging trends and forge new pathways for international cooperation.

Medical Taiwan 2026, organized by the Taiwan External Trade Development Council (TAITRA), concluded today (June 27) at TWTC Hall 1. The three-day exhibition attracted visitors from 63 countries, with Japan, Thailand, Vietnam, the Philippines, and South Korea ranking among the top five visitor markets. This year’s exhibition also drew a strong international presence, with nearly 20 buyer groups organized by industry associations from around the world. Notably, first-time buyer groups included medical device manufacturers, medical software industry associations, and hospital associations from emerging and strategic markets such as Saudi Arabia, Australia, Hungary, India, and Vietnam, underscoring Medical Taiwan’s growing international appeal as a leading platform in Asia for smart healthcare trade and industry exchange.

Taiwan continues to strengthen its global competitiveness through its comprehensive industrial supply chain, spanning semiconductors, precision instruments, and electronic manufacturing, while integrating advanced medical device manufacturing with AI-driven innovation. During the exhibition, the One-on-One Procurement Meetings facilitated approximately 580 business-matching sessions between 107 international buyers from 46 countries—including Japan, Brazil, Israel, Hungary, the UK, Kazakhstan, Egypt, the US, Vietnam, Australia, Germany, Mexico, Romania, and Nigeria—and nearly 200 exhibitors. The meetings are projected to generate US$168.7 million in business opportunities, further underscoring the competitiveness of Taiwan’s smart healthcare industry on the global stage.

Exhibitors responded positively to this year’s exhibition, noting significant increases in both the number and diversity of international buyers compared with previous editions. Buyers also expressed strong interest in smart healthcare solutions, digital health technologies, and high-value medical devices. The strong demand highlights growing international interest in Taiwanese medical technologies and reinforces Medical Taiwan’s role as a key platform for international buyers to explore industry trends and develop partnerships across Asia.

Themed activities held throughout the exhibition were also well received. The “Taiwan Patent GO” pavilion, established by the Taiwan Intellectual Property Office (TIPO), showcased innovative patented technologies in precision medicine, AI-enabled healthcare, and assistive devices. The pavilion attracted buyers from Singapore, Qatar, the US, India, and Romania, who engaged in discussions on technology collaboration and market expansion.

The “RX FOR FUTURE Forum,” which focused on global healthcare trends, featured Professor Bruce Leff of Johns Hopkins University, a pioneer of the Hospital-at-Home (HaH) model, along with experts from Japan, Israel, and Australia. The speakers shared insights into home-based medical care and smart nursing. Experts highlighted AI, telemedicine, and digital health as key technologies driving the transformation of healthcare delivery at home. The “Digital Healthcare Pavilion” further showcased these trends through scenario-based demonstrations of Taiwan’s integrated hardware and software capabilities, attracting in-depth inquiries from buyers from Mexico and Chile, as well as representatives of the Australian Medical Software Industry Association.

Furthermore, the M-novator Demo Day, held on the first day of the exhibition, successfully connected domestic and international startups with medical institutions and investors. The event attracted financial institutions and investment firms, including Fubon Financial Holding, Biopro Bioteck, and CDIB Capital, facilitating connections between innovative technologies and capital markets while strengthening international collaboration in Taiwan’s smart healthcare sector.

TAITRA stated that Medical Taiwan 2026 successfully brought together players from the global healthcare supply chain and fostered cross-sector innovation, further reinforcing Taiwan’s position as a leading hub for smart healthcare collaboration in Asia. Looking ahead, Medical Taiwan will continue to serve as a premier platform for smart healthcare trade and innovation, working with international partners to promote sustainable industry development and create new opportunities for global collaboration and business growth.

AI for pre-surgery assessment, wearable rehabilitation technologies and live robotic gait demonstrations put the practical application of healthcare innovation at the centre of Medical Fair Asia, Medical Manufacturing Asia and the inaugural RehaCare Asia, held at Marina Bay Sands from 9 to 11 September.

The three co-located events brought together 13,854 attendees from 73 countries and regions, with over 40% overseas visitors, alongside 1,000 exhibitors from 40 countries and regions. From Singapore General Hospital’s work on the PEACH chatbot for pre-surgery assessment to discussions on manufacturing, cybersecurity and market access, the three events connected clinical needs with the expertise required to bring new technologies into wider use.

The MotusAcademy × RehaCare Asia Leadership Forum drew a full house. During the session, St Luke’s Hospital and Robotimize signed a memorandum of understanding to test, refine and integrate rehabilitation robotics into clinical practice.

The inaugural ASEAN Care Readiness Index 2026, commissioned by Messe Düsseldorf Asia and launched during the events, highlighted the challenge of translating healthcare ambition into practice. Among 300 healthcare and MedTech leaders surveyed across six Southeast Asian markets, 94% considered their organisations prepared for the next three to five years, yet 54% identified technology implementation capability as a barrier to future readiness.

Lars Wismer, Managing Director of Messe Düsseldorf Asia, shared: “The technology is advancing quickly, but implementation must keep pace. Over the three days, we have seen what that means in practice: technology must fit clinical workflows, support healthcare professionals, work beyond the hospital and be viable to manufacture and scale. These are no longer separate conversations. They determine whether innovation ultimately reaches patients.”

Medical Fair Asia: AI moves closer to everyday clinical use

At Medical Fair Asia, practical applications of AI and connected healthcare showed how technology is beginning to move from experimentation into clinical workflows. At the Paradigm Shifts in Healthcare Seminar 2026, Singapore General Hospital shared its experience developing PEACH (PErioperative AI Chatbot) to support pre-operative assessments. The tool was developed around SGH’s institutional protocols for a clinic handling around 120 patients each day. Meanwhile, at the Future for Health (FTR4H) Conference Asia 2026, Quanta Computer explored continuous monitoring through wearable and ambient sensing across hospitals and homes.

Healthcare institutions and technology companies from Taiwan shared applications spanning AI-assisted cardiovascular and stroke detection, antimicrobial resistance prediction, generative AI to reduce administrative workloads, telehealth and remote monitoring. The sessions also examined how hospitals, homes and communities can be better connected, alongside pathways to clinically validate and commercialise locally developed MedTech.

The Innovation Partner Showcase zone brought emerging applications onto the exhibition floor, with Singapore-developed technologies from institutions including SUTD, the NUS Biorobotics Lab and Singapore Polytechnic, spanning wearable rehabilitation technologies, lightweight exoskeletons, AI enabled healthy ageing and AR/VR rehabilitation.

Sim Sovannara, CEO, Central Medical Services Co., Ltd, Cambodia shared that “To strengthen healthcare in Cambodia, we must look beyond our borders, learn from other healthcare systems and build meaningful international partnerships. Medical Fair Asia gives us access to new technologies, modern equipment and practical solutions that can improve patient care while supporting the continued development of our healthcare institutions.”

Medical Manufacturing Asia: A good technology still must become a viable product

At Medical Manufacturing Asia, implementation started further upstream: how to turn new technology into products that can be manufactured, commercialised and deployed safely at scale.

At the Medical Manufacturing Forum, A*STAR SIMTech / AIMfg examined barriers preventing manufacturers from scaling AI, including fragmented data and complex manufacturing environments. A*STAR Innovation Factory was introduced, focused on the decisions required to take technologies from prototype to manufacturable product, including whether companies should build capabilities internally, outsource, partner or acquire. Its central message was straightforward: a great technology does not automatically make a great product.

Market Entry Briefings added another consideration for companies looking to expand across the region. Regulatory strategy, intended use, product classification and the licences required to manufacture, import or distribute products can all affect how and when a technology reaches individual markets.

Medical Manufacturing Asia also named Nelipak Healthcare Packaging Pte Ltd the winner of its 2026 Marketing Excellence Award, with Toki Automation Pte Ltd receiving the Special Recognition Award.

Mr. Steven Toy, Chairman, Singapore Precision Engineering and Technology Association (SPETA) shared, “Medical Manufacturing Asia reflects the strength of the partnership between SPETA and Messe Düsseldorf Asia, combining our industry knowledge and local manufacturing network with the exhibition’s international reach. This edition has provided Singapore companies with an important platform to demonstrate their precision-engineering and advanced-manufacturing capabilities, connect with the global MedTech community and explore new business opportunities. We look forward to continuing to develop MMA in line with the evolving needs of the industry.”

RehaCare Asia: Recovery moves beyond hospital walls

At the inaugural RehaCare Asia, the question was not only what rehabilitation technology can do, but whether it can fit into the lives of patients and the work of healthcare professionals.

Speakers at the From Pilot to Practice: Closing Asia’s Rehabilitation Technology Adoption Gap forum stressed that clinical efficacy alone does not determine adoption. Patient goals, workflow fit, affordability, technical support, maintenance and whether technology can be used at home or in the community all matter.

Adjunct Associate Professor Dr Loh Yong Joo, Senior Consultant, Rehabilitation Medicine at Tan Tock Seng Hospital, highlighted the physical demands placed on therapists and the potential for robotics to reduce that burden while enabling patients to undertake more intensive rehabilitation. His message was clear: “Rehabilitation shouldn’t stop after discharge. It should continue in the community.”

The shift was reinforced at the Living Longer, Living Better Seminar, held in collaboration with Frost & Sullivan. Panellists described care moving from episodic treatment towards a connected journey spanning prevention, diagnosis, acute care, rehabilitation and community care, with technology helping to decentralise services and extend existing healthcare capacity. Another discussion challenged healthcare providers to design for the older adults of tomorrow, as today’s middle-aged population will enter later life with different expectations around independence, lifestyle, and how and where they receive care.

Practical application was also on display through Locomotor Therapy in Practice, which brought together robotic gait training, body weight-supported treadmill training and overground rehabilitation in a live patient demonstration.

Jenny Shih, an exhibitor with OPPO Medical’s Global Sales and Marketing team, said: “With so many medical exhibitions taking place around the world, the quality of the support team and the range of services available to exhibitors are crucial. Medical Fair Asia and RehaCare Asia gave us a strong platform to stay connected with our clients and business partners, while helping us stand out within a competitive international market.”

The co-located format brought clinical teams, researchers and technology suppliers together with manufacturing and market-access expertise, connecting participants across the development and adoption of healthcare technologies. The debut of RehaCare Asia extended that focus to rehabilitation, independence and care in homes and communities.

Looking ahead, Medical Fair Thailand and RehaCare Asia will take place in Bangkok from 8 to 10 September 2027. Medical Fair Asia, Medical Manufacturing Asia and RehaCare Asia will return to Singapore from 13 to 15 September 2028.

For updates on future editions, visit the official websites for Medical Fair Asia, Medical Manufacturing Asia and RehaCare Asia.

The T1D screening kit will initially be available across Europe and in markets that accept CE IVD-marked products. It is not cleared by the US Food and Drug Administration (FDA). The assay relies on capillary dried blood spot (DBS) samples and is processed on Revvity’s GSP instrument — a platform already widely used in newborn screening programmes. The workflow integrates reagents, instrumentation, and dedicated software into a unified system.

The GSP T1D 3plex kit was specifically developed to meet the requirements of emerging national T1D screening programmes. It forms part of Revvity’s broader diabetes portfolio, which spans research, clinical testing, and service models aimed at supporting healthcare systems at multiple levels.

Earlier identification of autoantibody presence is expected to support timely intervention and access to disease-modifying treatment, which remains a core objective for national health programmes tracking paediatric diabetes risk.

Revvity’s Vice-President and Reproductive Health General Manager, Anna Godenhjelm, commented on the significance of the launch: “The launch of the GSP T1D 3plex kit marks an important step forward for Revvity’s expansion into child health screening. This milestone demonstrates how our expertise in newborn screening can be leveraged to advance earlier detection in new areas of healthcare.”

On-Site and Off-Site Testing Services in Partnership with Sanofi

Revvity plans to present details on its T1D screening kit on-site installation and off-site testing services at the European Association for the Study of Diabetes meeting in Milan, Italy. These services have been developed in partnership with Sanofi and represent an extension of the company’s commitment to supporting national diabetes detection initiatives across Europe.

In a related development, Revvity received FDA clearance in May for a total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This offering enables direct ChLIA measurements of SHBG, total testosterone, and free testosterone, delivering both first-line and second-line diagnostic capabilities for identifying suspected hypogonadism in men.

The autoantibody detection capabilities embedded in the GSP T1D 3plex kit, combined with Revvity’s established footprint in newborn screening, position the company to support the growing demand for early-stage paediatric disease identification across European healthcare markets.

The system is designed to address the challenges patients face between appointments, such as managing treatment side effects, addressing new symptoms, and answering complex questions about their diagnosis. By feeding insights from member responses back into the system, the partnership aims to refine future guidance and improve clinical outcomes over time. According to Amy Flaster, MD, Cigna’s chief medical officer, bringing the power of OpenAI to the group will better connect patients to specialized resources and support, whether they are dealing with the physical impact of treatment or the emotional burden of a diagnosis.

Expansion of Cigna’s Digital Health Infrastructure

The collaboration with OpenAI follows other significant artificial intelligence initiatives already established by The Cigna Group. In July, the company launched Pharmacy Forward, a $100 million AI-driven program under Accredo, designed to expand personalized care management within its health plans. The group has reported that these expanded programs have already contributed to a 42% reduction in avoidable hospital stays among engaged members. By further integrating AI in clinical workflows, Cigna seeks to continue this trend of improving healthcare efficiency through data-driven insights.

This partnership adds Cigna to a growing list of major health insurers collaborating with artificial intelligence firms to modernize their operations. Other recent industry moves include Optum’s partnership with Anthropic in July and Elevance Health’s 2023 agreement with OpenAI to provide enterprise ChatGPT access and training to its workforce. The deal reflects a broader industry shift toward utilizing generative AI to synthesize complex healthcare information and provide more timely, personalized intervention for members managing chronic or complex conditions.

The expansion is particularly critical for the estimated 70% of countries that report weak or inadequate regulatory systems for health products. By broadening the prequalification programme for medical devices, WHO aims to improve equitable access to technologies such as male and female condoms, intrauterine devices (IUDs), and computer-aided detection software for tuberculosis (CAD-TB). As part of this transition, the prequalification of condoms and IUDs has been transferred from the United Nations Population Fund (UNFPA) to WHO. Additionally, male circumcision devices have been integrated into this broader framework to support voluntary medical services that can reduce the risk of HIV acquisition in men by approximately 60%.

Dr. Sylvie Briand, WHO Chief Scientist and Assistant Director-General a.i. for Health Systems, Access and Data, stated: “Everyone, everywhere, should be able to rely on medical devices that are safe, effective and meet high standards of quality. By expanding WHO prequalification, we are strengthening confidence in these essential health products and helping countries expand equitable access to the technologies people need to protect and improve their health.” The inclusion of CAD-TB software also introduces artificial intelligence-driven digital health technology into the programme, facilitating earlier detection and treatment in high-burden countries.

Current operational bottlenecks in radiation oncology planning frequently involve coordinating complex data streams across disparate hardware and software systems. Clinical workflows often require up to 17 discrete manual stages for importing treatment parameters, and analyses of clinical cases indicate more than 44 variations in treatment planning pathways. These inefficiencies are primarily driven by unstructured information, such as clinical progress notes, pathology summaries, and disconnected imaging files. The collaboration evaluates an AI query system designed to extract and synthesize both structured electronic health record data and unstructured clinical assets, allowing clinicians to retrieve patient histories and anatomical landmarks using natural language queries.

Integration and Clinical Performance

The project evaluates a system architecture capable of parsing DICOM imaging sets, medical texts, and historical dosimetry plans into unified contextual profiles. This functional capability operates alongside the workflow orchestration engine of the iRT platform, which automates cross-department handoffs between medical physicists, dosimetrists, and radiation oncologists. By incorporating these generative AI tools, the research aims to minimize manual data curation and prevent configuration errors during the dose planning phase.

The current research builds upon previous software integration efforts between the two entities. Clinical workflow solutions implemented at Massachusetts General Hospital across more than 11,000 treatment plans successfully reduced the operational interval between patient intake and treatment initiation from 30 days to eight days. The ongoing deployment phase explores the integration of generative retrieval algorithms into broader multimodality oncology workflows, including MR-guided therapy and molecular radiotherapy guidance, to improve operational throughput in high-volume cancer centers.

Addressing Revenue Cycle Inefficiencies at the Source

Revenue cycle teams across the country continue to lose significant time and financial resources managing downstream problems — including claim denials, missing documentation, authorization failures, inaccurate charge capture, and delayed payments. Oracle Health is responding to these systemic challenges by embedding AI upstream across the full revenue cycle spectrum: from scheduling and financial clearance through clinical documentation, charge capture, billing, and payment processing.

The goal, as articulated by Oracle Health, is to identify risks early, streamline routine workflows, and connect clinical, financial, payer, and operational data before these gaps translate into payment delays and revenue loss.

Seema Verma, Executive Vice President and General Manager of Oracle Health and Life Sciences, spoke directly to the strategic intent behind the initiative: “AI gives us an opportunity to prevent revenue cycle problems before they lead to denials and delayed payments. Oracle Health is delivering a comprehensive revenue cycle solution that brings AI across the front, middle, and back office, connecting clinical and financial workflows from the first patient interaction through payment. This can help healthcare organizations reduce administrative work and revenue leakage, get paid faster, and strengthen their financial stability so they can stay focused on delivering excellent patient care.”

Connecting Fragmented Systems Through Native AI

A core challenge facing many healthcare organizations today is the fragmentation of clinical, financial, payer, provider, and operational activities across disconnected systems and manual processes. These disconnects create inefficiencies, reimbursement delays, and mounting administrative burdens.

Oracle Health’s AI revenue cycle approach addresses this by connecting workflows across patient access, clinical documentation, patient accounting, contract intelligence, payment operations, enterprise analytics, and financial management — all within existing Oracle Health infrastructure. Organizations can adopt these embedded AI capabilities at their own pace, without the disruption of wholesale system replacement.

New Embedded AI Capabilities

The newly announced AI capabilities, planned for general availability in the coming months, span five key areas of the revenue cycle:

Prior Authorization — Checks coverage, retrieves and pre-fills documentation requirements, attaches clinical evidence, coordinates authorization activities, and supports payer interactions to reduce authorization-related delays and denials.

Clinical Document Quality Integrity — Reviews reimbursement-related documentation, identifies gaps, and surfaces contextual recommendations to improve documentation and coding quality.

Charge Capture and Integrity — Analyzes clinical and reimbursement context, including modifiers and service details within charge review workflows, to limit revenue leakage and optimize reimbursement outcomes.

Medical Coding for Professional Fees — Analyzes clinical documentation and patient context to surface coding recommendations within existing workflows, supporting reimbursable claim readiness.

Appeal Management — Analyzes remittance data, identifies payment variances, and automates the creation of appeal packets when an appeal decision is made, helping reduce turnaround times.

Integration with Enterprise Financial Operations

As part of its planned product direction, Oracle Health intends to extend the connectivity of AI revenue cycle workflows into broader enterprise financial operations. This includes financial reconciliation, revenue accounting, treasury management, and analytics through platforms such as Oracle Fusion Cloud Applications. The intent is to enable health systems to connect reimbursement activity, financial operations, and enterprise analytics to support more informed operational and financial decision-making.

Strengthening Financial Stability Across Healthcare Organizations

The overarching aim of these AI revenue cycle capabilities is to help healthcare organizations reduce administrative overhead, limit revenue leakage, accelerate payments, and maintain the financial stability required to sustain quality patient care. By embedding intelligence across both the clinical and financial sides of the revenue cycle, Oracle Health is positioning its portfolio as a connected, end-to-end solution for revenue performance optimization.